PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

Go online to PeerView.com/TWX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in cardiovascular medicine discuss the benefits of telemedicine when screening and caring for patients with nonvalvular atrial fibrillation (NVAF). Upon completion of this activity, participants will be able to: Identify the benefits of using telemedicine and remote care services to diagnose and manage patients with NVAF, Describe ways in which telemedicine and remote care services can be used to increase patient awareness about the risks of NVAF and overcome healthcare disparities to improve healthcare delivery for patients with untreated NVAF, Operationalize best practices to design processes and procedures for a telemedicine or remote care program to manage patients with NVAF and prevent stroke, Employ telemedicine and remote care services to diagnose and manage patients with NVAF during the COVID-19 pandemic and beyond.

Exploring the Present and Future of BTK Inhibition in B-Cell Malignancies: Expert Insights on Practical Implications for Patient Management

Go online to PeerView.com/TCX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is a clinically complex disease that is often undiagnosed or misdiagnosed. The mechanisms behind its pathophysiology are not yet fully understood, but HCM has multiple underlying drivers, including cardiac muscle hypercontractility. It is the most common genetic heart disease and follows an autosomal dominant pattern with a poorly defined prevalence, age-dependent penetrance, and widely variable outcomes, as no medications are specifically indicated for its treatment. Encouragingly, recent advances in precision medicine and emerging treatment strategies, such as targeted therapy with small molecules, have demonstrated improvements in imaging parameters and quality of life. In this engaging activity, based on a recent live web broadcast, leading experts examine the pathophysiology of HCM, current guideline recommendations, and patient-centered care, as they explore the latest evidence for myosin inhibitors. Compelling videos of patients with HCM are shown to articulate first-person perspectives on how this condition affects individuals and their families. Upon completion of this activity, participants should be better able to: Differentially diagnose patients suspected of having HCM consistent with current guidance and recent advances in testing and technology to promote early recognition, Recognize the burdens that patients with HCM experience and the effects that diagnosis and treatments can have on their lifestyle, activity level, and emotional well-being, Select from among current and emerging therapeutic strategies based on their efficacy, safety, and ability to address the underlying pathophysiology of HCM, Collaborate with multidisciplinary and interprofessional care colleagues to personalize HCM management plans consistent with new recommendations, including imaging and genetic testing, medical therapies, sudden cardiac death risk assessment and prevention, and lifestyle considerations, such as referring patients to HCM centers.

Go online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recurrence. With great progress in clinical research come questions about how to translate it into improvements in clinical practice. Which patients are/are not candidates for adjuvant CDK4 and 6 inhibition based on the recent FDA approval and updated ASCO recommendations? What is the role of Ki-67 testing in determining patient eligibility for treatment? How should risk be assessed to inform treatment selection and improve outcomes in patients with HR+/HER2- EBC? These questions and others are answered in this succinct educational activity to help make the most of this new adjuvant therapy option for the benefit of patients. Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence. Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 and 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease. Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team-based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.